However, our data overall contribute to strengthen the potential promising benefit of combining miRNA-selective mTOR targeting and mTOR inhibitors as potent therapeutic tools in advanced lung carcinoids, supporting also that miR-100 expression testing might be a potential predictive biomarker of response to mTOR inhibition strategies. Here, MTOR is linked to lung carcinoid tumor.